3D-QSAR AND DOCKING STUDIES OF NOVEL QUINAZOLINE ANALOGUES AS ORAL INHIBITORS TOWARDS AP-1 AND NF-κB

Abstract

Three-dimensional quantitative structure-activity relationship (3D-QSAR) and Docking studies of novel quinazoline analogues, which are oral potential inhibitors towards the activator protein-1 (AP-1) and nuclear factor kappa B (NF-κB), have been carried out. The 3D-QSAR study based on the comparative molecular field analysis (CoMFA) shows the established model having a significant statistical quality and excellent predictive ability, in which the correlation coefficient R is 0.972 and cross-validation coefficient q2 is 0.619. The Docking results also show a considerable correlation (or trend) between the energy scores and the corresponding experimental values for these compounds at some sites. Meanwhile, it is very interesting to find the binding sites just fall on the joint regions between AP-1 (or NF-κB) and DNA. It may be the reason that the quinazoline analogues have inhibition function because their existence on these joint regions can effectively prevent free AP-1 and NF-κB from binding to DNA. Based on the established 3D-QSAR and Docking analyses, six new compounds of quinazoline analogues with higher inhibitory activities were theoretically designed and presented. The above results can offer some valuable theoretical references for the pharmaceutical molecular design as well as the action mechanism analysis.